{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:10:17Z","timestamp":1769123417132,"version":"3.49.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>We studied the safety and reactogenicity SARS-CoV-2 mRNA vaccines in transplant recipients because immunosuppressed patients were excluded from vaccine trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>US transplant recipients were recruited into this prospective cohort study through social media; those who completed the full vaccine series between December 9, 2020 and March 1, 2021 were included. We collected demographics, medical history, and safety information within 7 d after doses 1 and 2 (D1, D2). Associations between characteristics and reactions were evaluated using modified Poisson regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>We studied 741 transplant recipients who underwent BNT162b2 (54%) or mRNA-1273 (46%) vaccination. Median (interquartile range) age was 60 (44\u201369) y, 57% were female, and 10% were non-White. Although local site reactions decreased after D2 (85% D1 versus 78% D2, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001), systemic reactions increased (49% D1 versus 69% D2, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001). Younger participants were more likely to develop systemic symptoms after D1 (adjusted incidence rate ratio [aIRR] per 10 y\u2009=\u2009<jats:sub>0.85<\/jats:sub>0.90<jats:sub>0.94<\/jats:sub>, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001) and D2 (aIRR per 10 y\u2009=\u2009<jats:sub>0.91<\/jats:sub>0.93<jats:sub>0.96<\/jats:sub>, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001). Participants who experienced pain (aIRR\u2009=\u2009<jats:sub>1.11<\/jats:sub>1.66<jats:sub>2.47<\/jats:sub>, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.01) or redness (aIRR\u2009=\u2009<jats:sub>1.83<\/jats:sub>3.92<jats:sub>8.41<\/jats:sub>, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.01) were more likely to develop an antibody response to D1 of mRNA vaccines. No anaphylaxis, neurologic diagnoses, or SARS-CoV-2 diagnoses were reported. Infections were minimal (3% after D1, &lt;0.01% after D2). One patient reported incident acute rejection post-D2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>In solid organ transplant recipients undergoing mRNA vaccination, reactogenicity was similar to that reported in the original trials. Severe reactions were rare. These early safety data may help address vaccine hesitancy in transplant recipients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003780","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T08:37:41Z","timestamp":1618648661000},"page":"2170-2174","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":67,"title":["Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients"],"prefix":"10.1097","volume":"105","author":[{"given":"Michael T.","family":"Ou","sequence":"first","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Boyarsky","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer D.","family":"Motter","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross S.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aura T.","family":"Teles","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake A.","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle R.","family":"Krach","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedant S.","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Werbel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin K.","family":"Avery","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan B.","family":"Massie","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorry L.","family":"Segev","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."},{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Garonzik-Wang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses.","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology.","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases.","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"217","DOI":"10.15585\/mmwr.mm7006e3","article-title":"COVID-19 vaccination intent, perceptions, and reasons for not vaccinating among groups prioritized for early vaccination\u2014United States, September and December 2020.","volume":"70","author":"Nguyen","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R8-20250607","article-title":"Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients.","author":"Boyarsky","journal-title":"Transplantation"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"R13-20250607","first-page":"e214385","article-title":"Immunogenicity of a single dose of SARS-CoV-2 messenger RNA Vaccine in solid organ transplant recipients.","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data.","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"125","DOI":"10.15585\/mmwr.mm7004e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine \u2014 United States, December 14\u201323, 2020.","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity.","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"npj Vaccines"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T16:12:17Z","timestamp":1749312737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003780","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}